Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes

被引:24
作者
Fiechter, Michael [1 ,2 ,3 ]
Ghadri, Jelena R. [1 ]
Jaguszewski, Milosz [1 ]
Siddique, Asim [1 ]
Vogt, Severin [1 ]
Haller, Raphael B. [1 ]
Halioua, Robin [1 ]
Handzic, Armin [1 ]
Kaufmann, Philipp A. [2 ,3 ]
Corti, Roberto [1 ]
Luescher, Thomas F. [1 ,3 ]
Templin, Christian [1 ]
机构
[1] Univ Zurich Hosp, Dept Cardiol, Ctr Cardiovasc, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Radiol, CH-8091 Zurich, Switzerland
[3] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
acute coronary syndrome; cardiac function; inflammation; outcome; C-REACTIVE PROTEIN; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; ATHEROSCLEROTIC PLAQUES; ARTERY-DISEASE; HEART-DISEASE; RISK; MORTALITY; ADMISSION; MARKERS;
D O I
10.2459/JCM.0b013e3283609350
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsInflammation is a key factor in the long-term outcome of acute coronary syndromes (ACS). The aim of the present study was to evaluate inflammatory markers in patients with ACS as predictors for major adverse cardiovascular events (MACE) and hard events.MethodsThis study included 1548 patients with ACS. C-reactive protein (CRP), white blood count (WBC), and their subtypes were analyzed during hospitalization. Receiver operator characteristic (ROC) and Kaplan-Meier survival curves were used to assess the predictive value and hard events (nonfatal myocardial infarction and cardiac death) and MACE (hard events, hospitalization for cardiac causes, late revascularization and stroke) were obtained during 30 days.ResultsROC analysis of CRP and WBC to predict adverse events revealed cut-offs of 47.5ng/l and 16.6x10(3)/l for MACE and 93.5ng/l and 16.6x10(3)/l for hard events. The cumulative adverse event rates were significantly higher in patients with increased CRP (47.5ng/l; 17 versus 4%, P<0.001) and WBC (16.6x10(3)/l; 21 versus 5%, P<0.001) for MACE and with elevated CRP (93.5ng/l; 16 versus 2%, P<0.001) and WBC (16.6x10(3)/l; 18 versus 2%, P<0.001) for hard events, demonstrating highest event rates with elevation of both inflammatory markers: (28 versus 5%, P<0.001) for MACE and (26 versus 2%, P<0.001) for hard events. Analysis of CRP and WBC further revealed a substantial negative correlation with left ventricular function (P<0.001). Moreover, markers of myocardial damage were significantly elevated in patients with abnormal CRP or WBC (P<0.001).ConclusionInflammatory markers such as CRP and WBC alone and, particularly, in combination are strong and independent predictors of outcome in patients with ACS.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
  • [41] Early Glucometabolic Profile in Patients with Acute Coronary Syndromes and Metabolic Syndrome
    Monteiro, Carlos M. C.
    Oliveira, Luciene
    Izar, Maria C. O.
    Helfenstein, Tatiana
    Santos, Andreza O.
    Fischer, Simone M.
    Barros, Sahana W.
    Pinheiro, Luiz F. M.
    Carvalho, Antonio C. C.
    Fonseca, Francisco A. H.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2009, 92 (02) : 94 - 99
  • [42] Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry
    De Luca, Leonardo
    Gulizia, Michele M.
    Gabrielli, Domenico
    Meessen, Jennifer
    Mattei, Luisa
    D'Urbano, Maurizio
    Colivicchi, Furio
    Temporelli, Pier L.
    Borghi, Claudio
    Desideri, Giovambattista
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (02) : 393 - 401
  • [43] Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
    Phrommintikul, Arintaya
    Kuanprasert, Srun
    Wongcharoen, Wanwarang
    Kanjanavanit, Rungsrit
    Chaiwarith, Romanee
    Sukonthasarn, Apichard
    EUROPEAN HEART JOURNAL, 2011, 32 (14) : 1730 - 1735
  • [44] Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention
    Ndrepepa, Gjin
    Keta, Dritan
    Byrne, Robert A.
    Schulz, Stefanie
    Mehilli, Julinda
    Seyfarth, Melchior
    Schoemig, Albert
    Kastrati, Adnan
    HEART AND VESSELS, 2010, 25 (01) : 27 - 34
  • [45] Novel targets and strategies addressing residual cardiovascular risk in post-acute coronary syndromes patients
    Cancro, Francesco Paolo
    Bellino, Michele
    Silverio, Angelo
    Di Maio, Marco
    Esposito, Luca
    Palumbo, Rossana
    La Manna, Martina
    Formisano, Ciro
    Ferruzzi, Germano
    Vecchione, Carmine
    Galasso, Gennaro
    TRANSLATIONAL MEDICINE AT UNISA, 2024, 26 (02):
  • [46] Inflammation in atherosclerosis and acute coronary syndromes
    Gram, J
    MIDLIFE HEALTH - CURRENT CONCEPTS AND CHALLENGES FOR THE FUTURE, 2002, 1229 : 95 - 102
  • [47] Serum interleukin-10 levels and adverse events in patients with acute coronary syndrome: a systematic review and meta-analysis
    Liu Jun
    Jia Yanjun
    Li Xiaolin
    Xu Ruixia
    Zhu Chenggang
    Guo Yuanlin
    Wu Naqiong
    Li Jianjun
    CHINESE MEDICAL JOURNAL, 2014, 127 (01) : 150 - 156
  • [48] The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes
    Kaminska, Joanna
    Koper, Olga M.
    Siedlecka-Czykier, Edyta
    Matowicka-Karna, Joanna
    Bychowski, Jerzy
    Kemona, Halina
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2018, 25 (07) : 1263 - 1271
  • [49] Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials
    De Rosa, Salvatore
    Caiazzo, Gianluca
    Torella, Daniele
    Indolfi, Ciro
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (02) : 1298 - 1305
  • [50] Impact of cardiovascular risk factors and disease on length of stay and mortality in patients with acute coronary syndromes
    Loudon, B. L.
    Gollop, N. D.
    Carter, P. R.
    Uppal, H.
    Chandran, S.
    Potluri, R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 220 : 745 - 749